JERUSALEM-(BUSINESS WIRE)- Teva Pharmaceutical Industries Ltd, (NYSE and TASE: TEVA) today announced the launch of ALYQ, a generic version of ADCIRCA 1 (tadalafil)
Teva Pharmaceutical Industries Ltd, (NYSE and TASE: TEVA) today announced the exclusive first-to-file launch of a generic version of Cialis 1 (tadalafil)
Teva Pharmaceutical Industries Ltd, (NYSE and TASE: TEVA) today announced the exclusive first-to-file launch of a generic version of Cialis 1 (tadalafil)
Teva Pharmaceutical Industries Ltd, (NYSE and TASE: TEVA) today announced the exclusive first-to-file launch of a generic version of Cialis 1 (tadalafil)
Teva Pharmaceutical Industries (Teva) announced in September 2025 that it was launching generic tadalafil but would be delaying the launch of its higher-dose Suboxone
Teva Pharmaceutical Industries Ltd, (NYSE and TASE: TEVA) today announced the exclusive first-to-file launch of a generic version of Cialis 1 (tadalafil)
NDCs - National Drug Codes; Teva Pharmaceuticals, Inc. - NDC products NDC labeler, manufacturer of drugs and pharmaceuticals Tadalafil: Teva Pharmaceuticals
Teva Pharmaceutical Industries Ltd, (NYSE and TASE: TEVA) today announced the exclusive first-to-file launch of a generic version of Cialis 1 (tadalafil)
In January 2025, Teva Pharmaceutical Industries (Teva) received US Food and Drug Administration (FDA) approval for its first generic version of Sab Generics and biosimilars Initiative Teva launches generic tadalafil but delays launch of generic Suboxone.
Comments